Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form before any study-related procedures begin
• People aged 18 or older at the time of signing consent
• People who have been diagnosed with a specific type of blood cancer called large B-cell lymphoma (LBCL), confirmed by laboratory testing, and whose cancer cells carry a protein called CD20 — this includes several subtypes of LBCL (confirm with trial site for full list)
• People whose lymphoma has come back after being in remission for more than 6 months, or whose lymphoma did not respond to treatment or got worse within 6 months of finishing their last treatment
• People whose cancer has a specific gene change — either a deletion or mutation in a gene called TP53 — confirmed by specialist laboratory testing
• People who are not suitable candidates for a stem cell transplant using their own cells (ASCT), for reasons such as being aged 70 or older, having serious organ problems, having a lower ability to carry out daily activities, choosing not to have the transplant, or having other significant health conditions as determined by the treating doctor
• People who have at least one measurable area of disease at the start of the trial — either a lymph node measuring at least 1.5 cm, or a lesion outside the lymph nodes measuring at least 1.0 cm
• People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (confirm with trial site what this means for individual circumstances)
• People expected to live for at least 12 weeks, as assessed by the treating doctor
• People with blood counts at an adequate level (unless low counts are directly caused by the lymphoma affecting the bone marrow or spleen)
• People who are willing to follow all study procedures, including contraception requirements if there is a possibility of pregnancy during the trial

Who may not be able to join:

• People who have previously had a stem cell transplant using donor cells, or who have had an organ transplant
• People whose lymphoma has spread to the central nervous system (brain and spinal cord) and is currently active
• People with active autoimmune conditions that require treatment with medicines that suppress the immune system
• People with uncontrolled infections, including active hepatitis B, hepatitis C, or HIV
• People who have previously been treated with Glofitamab, another bispecific antibody that targets both CD20 and CD3, or a combination of a PD-1 inhibitor with a medicine called Lenalidomide
• People who have had a serious allergic reaction to monoclonal antibody medicines or to any ingredient in the study drugs
• People who are currently taking part in another clinical trial involving an experimental treatment
• People who have used certain immune-suppressing medicines within the 14 days before enrolling (some steroid medicines used to treat lymphoma or manage side effects may be an exception — confirm with trial site)
• People who are pregnant or breastfeeding
• People who have psychological, social, or medical circumstances that the treating doctor believes could affect their ability to follow the study or could put their safety at risk

Important: Always verify eligibility with the trial site directly before applying.